Hadassah Medical Organization
Jerusalem, Israel
NCT Number: NCT00226551
Single nucleotide polymorphisms at codon 46 and 79 of the gene encoding for the ß2 adrenergic receptor (ß2AR) modify its pharmacological properties and may alter the response to ß2AR agonists. The goal of the present study was to evaluate the role played by the Arg16Gly and Gln27Glu polymorphisms on isoproterenol induced relaxation of internal mammary arteries segments ex-vivo.
Internal mammary leftover segments were collected from 96 patients undergoing coronary artery bypass graft operation. Four rings that were prepared from each specimen were allowed to reach equilibrium with physiological Krebs solution prior to precontraction with U46619. Using the organ bath technique, cumulative dose response curve of isoproterenol was constructed and mean EC50 calculated for each patient.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Not applicable
Jerusalem, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hadassah Medical Organization
Other
ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT04580017
Angina Pectoris, Angina, Unstable
Hammam Sousse, Sousse Governorate, Tunisia
View Trial DetailsNCT00248352
Arterial Occlusive Diseases, Arteriosclerosis
Ottawa, Ontario, Canada
View Trial DetailsNCT00241735
Cardiovascular Diseases, Coronary Disease
View Trial Details